![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF445 |
Gene summary for ZNF445 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF445 | Gene ID | 353274 |
Gene name | zinc finger protein 445 | |
Gene Alias | ZFP445 | |
Cytomap | 3p21.31 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | P59923 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
353274 | ZNF445 | HCC1_Meng | Human | Liver | HCC | 5.26e-51 | 7.60e-02 | 0.0246 |
353274 | ZNF445 | HCC2_Meng | Human | Liver | HCC | 2.03e-04 | -2.21e-02 | 0.0107 |
353274 | ZNF445 | HCC1 | Human | Liver | HCC | 1.93e-11 | 2.84e+00 | 0.5336 |
353274 | ZNF445 | HCC2 | Human | Liver | HCC | 9.57e-21 | 3.12e+00 | 0.5341 |
353274 | ZNF445 | HCC5 | Human | Liver | HCC | 6.16e-11 | 2.86e+00 | 0.4932 |
353274 | ZNF445 | S014 | Human | Liver | HCC | 3.78e-04 | 3.30e-01 | 0.2254 |
353274 | ZNF445 | S015 | Human | Liver | HCC | 9.35e-04 | 3.78e-01 | 0.2375 |
353274 | ZNF445 | S016 | Human | Liver | HCC | 2.28e-04 | 3.20e-01 | 0.2243 |
353274 | ZNF445 | S028 | Human | Liver | HCC | 5.29e-10 | 5.32e-01 | 0.2503 |
353274 | ZNF445 | S029 | Human | Liver | HCC | 1.86e-05 | 5.11e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF445 | SNV | Missense_Mutation | c.2430N>T | p.Arg810Ser | p.R810S | P59923 | protein_coding | deleterious(0) | possibly_damaging(0.709) | TCGA-97-7938-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | novel | c.2386N>C | p.Gly796Arg | p.G796R | P59923 | protein_coding | deleterious(0) | possibly_damaging(0.808) | TCGA-99-8032-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ZNF445 | SNV | Missense_Mutation | rs761608124 | c.652N>A | p.Asp218Asn | p.D218N | P59923 | protein_coding | tolerated(0.72) | benign(0.003) | TCGA-J2-8192-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
ZNF445 | SNV | Missense_Mutation | c.876N>T | p.Trp292Cys | p.W292C | P59923 | protein_coding | deleterious(0.01) | possibly_damaging(0.888) | TCGA-NJ-A4YI-01 | Lung | lung adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | c.326N>C | p.Gly109Ala | p.G109A | P59923 | protein_coding | tolerated(0.21) | benign(0.077) | TCGA-66-2766-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
ZNF445 | SNV | Missense_Mutation | novel | c.413N>G | p.Asp138Gly | p.D138G | P59923 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-85-8287-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ZNF445 | SNV | Missense_Mutation | novel | c.1204N>T | p.Thr402Ser | p.T402S | P59923 | protein_coding | tolerated(0.63) | benign(0.01) | TCGA-O2-A52Q-01 | Lung | lung squamous cell carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ZNF445 | SNV | Missense_Mutation | c.2329N>G | p.Leu777Val | p.L777V | P59923 | protein_coding | deleterious(0) | probably_damaging(0.985) | TCGA-CN-6023-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | erbitux | SD | |
ZNF445 | SNV | Missense_Mutation | rs201335323 | c.1586C>T | p.Ala529Val | p.A529V | P59923 | protein_coding | tolerated(1) | benign(0) | TCGA-CR-7388-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | PD |
ZNF445 | SNV | Missense_Mutation | novel | c.146N>T | p.Pro49Leu | p.P49L | P59923 | protein_coding | deleterious(0) | possibly_damaging(0.836) | TCGA-CV-7568-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |